Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Jun;51(6):2208-10.
doi: 10.1128/AAC.00871-06. Epub 2007 Apr 9.

Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants

Carmen D Zorrilla  1 , Russell Van Dyke, Arlene Bardeguez, Edward P Acosta, Betsy Smith, Michael D Hughes, Sharon Huang, D Heather Watts, Barbara Heckman, Eleanor Jiménez, George McSherry, Lynne Mofenson
Affiliations

Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants

Carmen D Zorrilla et al. Antimicrob Agents Chemother. 2007 Jun.

Abstract

Saquinavir boosted with low-dose ritonavir given with zidovudine and lamivudine was well tolerated by pregnant women and their infants. All mothers had <400 human immunodeficiency virus type 1 RNA copies/ml at delivery. Two had elevated liver transaminases and amylase. Seven infant adverse events were possibly treatment related (anemia, neutropenia, and hyperbilirubinemia).

PubMed Disclaimer

References

    1. Acosta, E. P., A. Bardeguez, C. D. Zorrilla, R. Van Dyke, M. D. Hughes, S. Huang, L. Pompeo, A. M. Stek, J. Pitt, D. H. Watts, E. Smith, E. Jimenez, L. Mofenson, and the Pediatric AIDS Clinical Trials Group 386 Protocol Team. 2004. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob. Agents Chemother. 48:430-436. - PMC - PubMed
    1. Acosta, E. P., C. Zorrilla, R. Van Dyke, A. Bardeguez, E. Smith, M. Hughes, S. Huang, J. Pitt, H. Watts, L. Mofenson, and the Pediatric AIDS Clinical Trials Group 386 Protocol Team. 2001. Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. HIV Clin. Trials 2:460-465. - PubMed
    1. AIDS Clinical Trials Group. Accessed 28 November 2006. Toxicity tables. http://rcc.tech-res-intl.com./tox_tables.htm.
    1. Bertz, R., C. Foit, X. Ye, L. Manning, B. Bernstein, C. Renz, A. Hsu, M. King, G. R. Granneman, and E. Sun. 2002. Pharmacokinetics of once-daily vs twice-daily Kaletra (lopinavir/ritonavir) in HIV+ subjects, abstr. 126. Program Abstr. 9th Conf. Retrovir. Opportun. Infect., Seattle, WA, 24 to 28 February 2002.
    1. Bryson, Y., A. Stek, M. Mirochnick, L. Mofenson, J. Connor, H. Watts, S. Huang, M. Hughes, B. Cunningham, L. Purdue, Y. Asfaw, and E. Smith for the PACTG 353 Team. 2002. Pharmacokinetics, antiviral activity and safety of nelfinavir (NFV) in combination with ZDV/3TC in pregnant HIV-infected women and their infants: PACTG 353 cohort 2, abstr. 795-W. Program Abstr. 9th Conf. Retrovir. Opportun. Infect., Seattle, WA, 24 to 28 February 2002.

Publication types

MeSH terms